The Cooper Companies, Inc. (COO)
Chart Events
Performance Outlook
| Previous Close | 388.22 |
| Open | 388.50 |
| Bid | 390.15 x 1100 |
| Ask | 390.29 x 1100 |
| Day's Range | 385.96 - 391.90 |
| 52 Week Range | 268.92 - 401.92 |
| Volume | 160,547 |
| Avg. Volume | 286,113 |
| Market Cap | 19.117B |
| Beta (5Y Monthly) | 0.82 |
| PE Ratio (TTM) | 8.57 |
| EPS (TTM) | 45.38 |
| Earnings Date | Jun 03, 2021 |
| Forward Dividend & Yield | 0.06 (0.01%) |
| Ex-Dividend Date | Jan 21, 2021 |
| 1y Target Est | 420.50 |
- GlobeNewswire
CooperCompanies Elects Maria Rivas, MD to Board of Directors
SAN RAMON, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) announced today that its Board of Directors has elected Dr. Maria Rivas as an independent director, effective July 1, 2021. “We are pleased to welcome Maria to our Board of Directors,” said Al White, President and CEO. “Maria brings a very valuable perspective with her background in fertility, medical affairs, product development, and global regulatory. We look forward to her advice and contributions as CooperCompanies continues to grow.” Dr. Rivas currently serves as Chief Medical Officer and Senior Vice President for the healthcare business of Merck KGaA, Darmstadt, Germany (which operates as EMD Serono in the US and Canada) where she leads the Global Pharmacovigilance, Medical Affairs and Evidence and Value Development (HEOR) teams in over 90 countries. Prior to that, Dr. Rivas served as Senior Vice President of Global Medical Affairs at Merck & Co (MSD), as Vice President of Global Medical Affairs at Abbvie, as Vice President of Oncology, General Medicine and Diagnostic Imaging Medical Affairs at Bayer Healthcare, and in various roles at Eli Lilly including Head of US Women’s Health Medical Affairs. Before joining Eli Lilly, Dr. Rivas was in private practice as an endocrinologist in Puerto Rico. Born in Cuba, Dr. Rivas grew up in Puerto Rico and still has many family, friends and professional connections there. In 2020, she was named among the Top 100 Most Influential Latinas by Latino Leaders Magazine. Cooper’s Board of Directors has welcomed several new directors and leaders in recent months. In November 2020, Teresa S. Madden was elected to the Board as an independent director. In March, Robert S. Weiss was elected Chairman of the Board, and William A. Kozy was elected Vice Chairman and Lead Director replacing A. Thomas Bender and Allan E. Rubenstein, M.D., respectively, who retired after many years of service. With the addition of Dr. Rivas, the Board will be comprised of eight directors, six of whom are independent. Cooper’s Board members are: Robert S. Weiss, Chairman of the BoardWilliam (Bill) A. Kozy, Vice Chairman and Lead DirectorColleen E. Jay, DirectorJody S. Lindell, DirectorTeresa S. Madden, DirectorGary S. Petersmeyer, DirectorDr. Maria Rivas, Director (effective July 1, 2021)Albert G. White III, President & Chief Executive Officer, CooperCompanies About CooperCompaniesCooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com. Contact:Kim DuncanVice President, Investor Relations and Risk Management925-460-3663ir@cooperco.com
- GlobeNewswire
CooperCompanies Acquires obp Medical
SAN RAMON, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO), today announced that CooperSurgical has acquired obp Medical Corporation, a U.S. based medical device company that develops and markets differentiated products including single-use vaginal speculums with integrated LED illumination. Commenting on the transaction, Al White, Cooper’s President and CEO said, “This acquisition is a great strategic fit that builds upon CooperSurgical‘s strong family of OB/GYN medical devices. obp Medical’s differentiated products will integrate seamlessly into our business and support our mission of advancing women’s healthcare.” The acquisition price is approximately $60 million, and the products being acquired generated approximately $10 million of trailing twelve-month revenue. The acquisition is expected to be neutral to Cooper’s non-GAAP earnings per share in fiscal 2021. About CooperCompaniesCooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com. About obp Medical Corporationobp Medical Corporation, headquartered in Lawrence, MA, is a privately held medical device company that develops and markets single-use illuminating medical devices. The company’s non-surgical product portfolio includes a suite of single-use vaginal specula with integrated LED lighting technology, as well as anoscopes, laryngoscopes, endoscopic seals and other related kits and accessories. These products are used in more than 13,000 physician offices, clinics, surgery centers, and hospitals throughout the U.S., and healthcare facilities worldwide. The company also previously had a surgical division however this was spun off prior to the acquisition. More information can be found at www.obpmedical.com. Forward Looking StatementsThis press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including statements regarding the acquisition of obp Medical including financial position, market position, product development and business strategy, expected cost synergies, expected timing and benefits of the transaction, difficulties in integrating entities or operations, as well as estimates of our and obp Medical’s future expenses, sales and diluted earnings per share are forward looking. In addition, all statements regarding anticipated growth in our net sales and anticipated market conditions, planned product launches and expected results of operations are forward-looking. To identify these statements look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Detailed descriptions of a number of important risk factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements can be found in our Securities and Exchange Commission filings, including under the “Business”, “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in our most recent Annual Report on Form 10-K, as such sections may be updated in our quarterly filings, copies of which are available on the Company’s website: www.coopercos.com. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law. Contact:Kim DuncanVice President, Investor Relations and Risk Management925-460-3663ir@cooperco.com
